Abstract:Fibrillogenesis of amyloid beta-protein (A beta) has been thought to be implicated in the progression of Alzheimer's disease (AD). Therefore, development of high-efficiency inhibitors is one of the strategies for the prevention and treatment of AD. Serum albumin has been found to capture A beta monomers through its hydrophobic groove and suppress amyloid formation, but the inhibition efficiency is limited. Inspired by the strong inhibition potency of a basic protein, human lysozyme, we have herein proposed to develop a basified serum albumin by converting carboxyl groups into amino groups with ethylenediamine conjugated on the protein surface. The idea was verified with both bovine and human serum albumins (BSA/HSA). Four basified BSA (BSA-B) preparations with amino modification degrees (MDs) from 8.0 to 41.5 were first synthesized. Extensive biophysical and biological analyses revealed that the inhibition potency significantly increased with increasing amino MD. BSA-B of the highest MD (41.5), BSA-B4, which had an isoelectric point of 9.7, presented strong inhibition on A beta(42) fibrillation at a concentration as low as 0.5 mu M, at which it functioned similarly with 25 mu M native BSA to impede 25 mu M A beta fibrillation. Cell viability assays also confirmed that the detoxification of 5 mu M BSA-B4 was superior over 25 mu M native BSA by increasing cell viability from 60.6% to 96.0%. Fluorescence quenching study unveiled the decrease of the binding affinity between A beta(42) and the hydrophobic pocket region of BSA-B4, while quartz crystal microbalance experiments demonstrated that the binding constant of BSA-B4 to A beta(42) increased nearly 5 times. Therefore, the increase of electrostatic interactions between BSA-B4 and A beta(42) was the main reason for its high potency. Hence, aminated BSA achieved a conversion of binding way to A beta from a mainly single-site hydrophobic binding to multiregional electrostatic interactions. Similar results were obtained with basified HSA preparations on inhibiting the amyloid formation and cytotoxicity. This work has thus provided new insights into the development of more efficient protein-based inhibitors against A beta fibrillogenesis.

The Inhibition of Serum Amyloid A Protein Aggregation by a Five-Residue Peptidomimetic: Structural and Morphological Insights

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Monitoring and Inhibition of Insulin Fibrillation by a Small Organic Fluorogen with Aggregation-Induced Emission Characteristics.

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibiting amyloid-like aggregation through bio-conjugation of proteins with polymer surfactant

Real-Time 3D Imaging and Inhibition Analysis of Human Serum Amyloid A Aggregations Using Quantum Dots

Inhibition behavior of Sennoside A and Sennoside C on amyloid fibrillation of human lysozyme and its possible mechanism

Structural studies of a serum amyloid A octamer that is primed to scaffold lipid nanodiscs

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

An aggregation inhibitor specific to oligomeric intermediates of Aβ42 derived from phage display libraries of stable, small proteins

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Diphenylalanine as a Reductionist Model for the Mechanistic Characterization of β-Amyloid Modulators

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Insight into the Inhibition Effect of Acidulated Serum Albumin on Amyloid Β-Protein Fibrillogenesis and Cytotoxicity.

Α-Helical Motif As Inhibitors of Toxic Amyloid-β Oligomer Generation Via Highly Specific Recognition of Amyloid Surface

A Computational Study of Self-Assembled Hexapeptide Inhibitors Against Amyloid-Β (aβ) Aggregation.

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Amyloid transformations of phenol soluble modulin α1 in Staphylococcus aureus and their modulation deploying a prenylated chalcone

Effect of a Short Peptide with Alternating L- and D-Amino Acid on the Aggregation and Membrane Damage of hIAPP

Modification of Serum Albumin by High Conversion of Carboxyl to Amino Groups Creates a Potent Inhibitor of Amyloid β-Protein Fibrillogenesis.

Metabolites from Marine Macroorganisms of the Red Sea Acting as Promoters or Inhibitors of Amylin Aggregation